SUPPLEMENT TO:
Financial Support Provided by
Optimizing Insulin Therapy: Basal Insulin and Beyond
Data suggest that in patients with type 2 diabetes, there has been little or no improvement in glycated hemoglobin (A1C) and other glycemic parameters over recent decades. In this digital roundtable discussion, the speakers address challenges faced every day in clinical practice, and provide practical advice regarding how primary care clinicians can overcome clinical inertia. The speakers particularly focus on how to manage patients who are treated with basal insulin, yet are unable to achieve good glycemic control.
This peer-reviewed publication was developed in adherence with Good Publication Practice (GPP3) guidelines. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship and have disclosed all potential conflicts of interest.
Video 1 of 3: Reasons Why We Don't Move Forward With Therapy
Video 2 of 3: When Should We Move Forward With Therapy
Video 3 of 3: Options For Therapuetic Intensification
Video not playing? Download Flash Player here
Video 1 of 3: Quality of Life for the HS Patient
In this video participants also discuss the psychological effects that HS has on some patients, and the roles that hygiene and some lifestyle choices, such as smoking, play in HS symptoms.
About the Panel
DISCLOSURES
- Dr. Aroda has had research contracts (clinical trials) within the past 12 months from: AstraZeneca/BMS, Calibra, Eisai, Elcelyx, Janssen, Novo Nordisk, Sanofi, and Theracos; has performed consultant activities within the past 12 months for American Diabetes Association, Medscape, Novo Nordisk, Sanofi, and Tufts
- Dr. Johhnson serves or has served on the speakers’ bureaus for Medtronic and Novo Nordisk; serves or has served on advisory panels for Novo Nordisk and Sanofi.
- Ms. Novak serves or has served on the speakers’ bureaus for AstraZeneca, Janssen, and Novo Nordisk; serves or has served on advisory boards and as a consultant for Novo Nordisk and Sanofi.
- Dr. Skolnik serves or has served on the advisory boards for AstraZeneca, Boehringer Ingelheim, Intarcia, Janssen Pharmaceuticals, Lilly, Sanofi, and Teva; serves or has served on the speakers’ bureaus for AstraZeneca and Boehringer Ingelheim; received research support from AstraZeneca and Sanofi.
ACKNOWLEDGEMENTS
- The authors wish to acknowledge the comments and review provided by Miss Davida Kruger. This review was funded by Sanofi US, Inc. The authors received writing/editorial support in the preparation of this material provided by Michael Van der Veer, PhD, of Excerpta Medica, funded by Sanofi US, Inc.